Multiple Myeloma in Young Adults-Insights From a Tertiary Care Cancer Centre in India [0.03%]
印度三级癌症诊疗中心的年轻成人多发性骨髓瘤患者的临床特征分析
George John,Sumeet Mirgh,Sachin Punatar et al.
George John et al.
Background: Multiple myeloma (MM) is primarily a disease of the elderly; data on young patients are limited. Aim: To evaluate the clini...
Jenyvette Hsia,Ella Derkzen,Cyrus C Hsia et al.
Jenyvette Hsia et al.
Novel Nonsense Mutation in SMARCD2 Gene Results in Dysplasia of All Myeloid Cell Lines [0.03%]
SMARCD2基因新 nonsense突变导致全部髓系细胞发育不良
Michelle A E Brouwer,Arie Arensman,H Rob Taal et al.
Michelle A E Brouwer et al.
Introduction: Specific granule deficiency type II (SGD2) is a rare heterogeneous congenital disease characterized by early-onset life-threatening infections. SGD2 is caused by autosomal recessive mutations in the SMARCD2 ...
Follow-Up of 3-Year Luspatercept Treatment in a Transfused ß-Thalassemia Patient. Bone Marrow: An Undervalued Iron Store [0.03%]
长期输血β-地中海贫血患者使用Luspatercept治疗的随访研究及铁蓄积情况:骨髓被低估的铁储存库
Matthias Bleeke,Claudia Niekrens,Soumya Datta et al.
Matthias Bleeke et al.
Introduction: Treatment with luspatercept may improve transfusion requirements in transfusion-dependent thalassemia (TDT), but the improved erythroid maturation in the bone marrow influences body iron distribution. ...
Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab [0.03%]
基线巨细胞病毒免疫球蛋白G水平可预测接受Elranatamab治疗的多发性骨髓瘤患者复发
Ukyo Kondo,Taku Kikuchi,Shotaro Sugita et al.
Ukyo Kondo et al.
Background: The cumulative incidence and risk of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma (RRMM) receiving elranatamab remain unclear. ...
Anaphylaxis During CAR T-Cell Infusion in an HIV-Positive Patient With High-Grade B-Cell Lymphoma: A Case Report and Literature Review [0.03%]
HIV患者发生CAR-T细胞输注相关过敏性休克1例及文献复习
Mostafa F Mohammed Saleh,Abdulrahman Nasiri,Ahmed Alahmadi et al.
Mostafa F Mohammed Saleh et al.
Chimeric antigen receptor (CAR) T-cell therapy is a highly effective treatment for relapsed or refractory large B-cell lymphoma (LBCL), but clinical experience in people living with HIV (PLWH) remains limited due to their exclusion from piv...
Pediatric T-Lymphoblastic Leukemia With Aberrant B-Cell Marker Expression: A Potential Role for Targeted Therapy [0.03%]
T细胞急性淋巴细胞白血病伴B系标志表达的分子特征及靶向治疗研究进展
Mahsa Khanlari,Wei Wang,Paul E Mead et al.
Mahsa Khanlari et al.
Background: Expression of B-cell antigens is rare in T-lymphoblastic leukemia/lymphoma (T-LBLL), and the significance is uncertain. Objective and methods:...
Alternative 5-Azacitidine 5-Day 100 mg/m2 Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment [0.03%]
5天100毫克/平方米与经典方案治疗骨髓增生异常肿瘤(MDS)和慢性粒单核细胞白血病(CMML)疗效相当:一项替代的5-阿扎胞苷剂量研究显示非劣效性
Gerasimos Tsilimidos,Filipe Martins,Mariangela Costanza et al.
Gerasimos Tsilimidos et al.
Introduction: 5-Azacitidine (AZA) is a major treatment option for myelodysplastic neoplasms (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Here we evaluate the efficacy and toxicity of an alternative AZ...
Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of DLBCL [0.03%]
供者来源的T细胞重定向使用Epcoritamab治疗allo-HSCT后早期复发的DLBCL患者并达到完全缓解
Yoshikazu Ikoma,Yuto Kaneda,Ryoma Shimazu et al.
Yoshikazu Ikoma et al.
Background: Epcoritamab, a bispecific CD3×CD20 antibody, offers a promising treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Its efficacy and safety after allogeneic hematopoietic stem cell transplantation (...